These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 18159711

  • 1. [HIP study--how to prevent hip fractures?].
    Itabashi A.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():286-92. PubMed ID: 18159711
    [No Abstract] [Full Text] [Related]

  • 2. [FACT study].
    Tanaka I, Oshima H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract] [Full Text] [Related]

  • 3. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
    Papapoulos SE.
    Ann Med Interne (Paris); 2000 Oct 28; 151(6):504-10. PubMed ID: 11104931
    [No Abstract] [Full Text] [Related]

  • 4. Potential impact of osteoporosis treatment on hip fracture trends.
    Melton LJ, Kanis JA, Johnell O.
    J Bone Miner Res; 2005 Jun 28; 20(6):895-7. PubMed ID: 15883627
    [No Abstract] [Full Text] [Related]

  • 5. [Osteoporosis. Fracture as alarm signal].
    MMW Fortschr Med; 2001 Oct 11; 143(41):56. PubMed ID: 11721665
    [No Abstract] [Full Text] [Related]

  • 6. [A good combination to achieve a reduced number of fractures: bone density measurements, drug therapy and hip protector].
    Johnell O, Ljunggren O, Mellström D.
    Lakartidningen; 2001 Jul 11; 98(28-29):3204-6. PubMed ID: 11496807
    [No Abstract] [Full Text] [Related]

  • 7. [Therapy of osteoporosis. Risk factors alone are not an indication].
    MMW Fortschr Med; 2001 Dec 06; 143(49-50):57. PubMed ID: 11813710
    [No Abstract] [Full Text] [Related]

  • 8. [Evidence of raloxifene on postmenopausal osteoporosis].
    Okano H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():374-80. PubMed ID: 18161135
    [No Abstract] [Full Text] [Related]

  • 9. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
    MMW Fortschr Med; 2007 Mar 29; 149(13):50. PubMed ID: 17672400
    [No Abstract] [Full Text] [Related]

  • 10. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group.
    N Engl J Med; 2001 Feb 01; 344(5):333-40. PubMed ID: 11172164
    [Abstract] [Full Text] [Related]

  • 11. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Feb 01; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 12. [Men also need bone protection].
    MMW Fortschr Med; 2006 Nov 16; 148(46):48-9. PubMed ID: 17615790
    [No Abstract] [Full Text] [Related]

  • 13. [Progress in external hip protectors].
    Koike T.
    Clin Calcium; 2006 Sep 16; 16(9):1493-99. PubMed ID: 16951474
    [Abstract] [Full Text] [Related]

  • 14. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun 22; 148(25):60-1. PubMed ID: 16859169
    [No Abstract] [Full Text] [Related]

  • 15. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis.
    Adami S.
    Bone; 2006 Feb 22; 38(2 Suppl 1):23-7. PubMed ID: 16434247
    [Abstract] [Full Text] [Related]

  • 16. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
    Hodsman AB, Hanley DA, Josse R.
    CMAJ; 2002 May 28; 166(11):1426-30. PubMed ID: 12054412
    [No Abstract] [Full Text] [Related]

  • 17. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials.
    Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A, Ross PD.
    Int J Clin Pract; 2006 Nov 28; 60(11):1394-400. PubMed ID: 17026515
    [Abstract] [Full Text] [Related]

  • 18. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD.
    Can Fam Physician; 1998 Feb 28; 44():327-32. PubMed ID: 9512836
    [Abstract] [Full Text] [Related]

  • 19. [Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
    Christoffersen H, Holmegaard SN.
    Ugeskr Laeger; 2005 Nov 21; 167(47):4454-6. PubMed ID: 16305763
    [Abstract] [Full Text] [Related]

  • 20. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
    MMW Fortschr Med; 2009 Mar 12; 151(11):46-7. PubMed ID: 19469206
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.